Document is current

Article History

Received: 22 June 2022

Accepted: 28 September 2022

First Online: 17 October 2022

Declarations

:

: Z.W. has received a postdoctoral fellow scholarship from Eli Lilly Canada Inc. and a postdoctoral fellowship from Fonds de Recherche du Québec-Santé (FRQS) (outside the submitted work). A.S.B., H.M., M.P.P., A.B. and V.M. have no competing interests to declare. B.A.P. has received speaker honoraria from Abbott, Medtronic, and Novo-Nordisk, has received research support to his research institute from Boehringer Ingleheim, Novo Nordisk, and the Bank of Montreal (BMO), and has served as a consultant to Boehringer Ingelheim, Abbott, Insulet, and Novo-Nordisk. R.R.L. has received research grants from Astra-Zeneca, Eli Lilly, Merck, Novo-Nordisk, Sanofi-Aventis, and Vertex Pharmaceutical, has been a consultant or member on advisory panels for Abbott, Amgen, Astra-Zeneca, Bayer, Carlina Technology, Dexcom, Eli Lilly, HSL Therapeutics, Insulet, Janssen, Medtronic, Merck, Novo-Nordisk, Pfizer, and Sanofi-Aventis, has received honoraria for conferences by Abbott, Astra-Zeneca, CMS Canadian Medical & Surgical Knowledge Translation Research group, CPD Network, Dexcom, Eli Lilly, Janssen, Medtronic, Merck, Novo-Nordisk, Sanofi-Aventis and Vertex Pharmaceutical. R.R.L. also benefits from unrestricted grants for clinical and educational activities from Abbott, Eli Lilly, Medtronic, Merck, Novo Nordisk and Sanofi-Aventis and holds intellectual property in the field of type 2 diabetes risk biomarkers, catheter life and the closed-loop system.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Centre Hospitalier de l’Université de Montréal (December 10, 2018/No. 18.232/MP-02–2019-7992).

: Informed consent was obtained from all individual participants included in the study.